Scientists target genetic flaw in relapsed blood cancer with new pill combo
NCT ID NCT06876142
Summary
This study is testing a new combination of two oral drugs, mirdametinib and sirolimus, for adults with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find a safe dose and see if the drugs can help control the cancer in patients whose tumors have specific changes in the KRAS or NRAS genes. Participants will take the pills at home for up to one year, with regular check-ups to monitor their health and the cancer's response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.